Loading organizations...
Founded in 2015 by Dr. George Church and Dr. Luhan Yang, eGenesis is a Cambridge, Massachusetts-based biotechnology company developing genetically engineered porcine organs for human transplantation using advanced CRISPR gene-editing technology to address the global organ shortage. The organization's lead product, EGEN-2784, targets kidney failure patients, while additional preclinical programs focus on treating severe heart and liver failure. Prior to clinical application, the firm generated extensive preclinical data in cross-species transplantation, presenting long-term survival and compatibility metrics at the 2023 IPITA-IXA-CTRMS Joint Conference. In March 2024, the enterprise achieved a major medical milestone when its lead product enabled the world’s first porcine kidney transplant into a living human patient. The biotechnology venture is backed by prominent institutional investors, including Lux Capital, with partner Peter Hébert involved in the firm's recent 2024 private financing efforts.
EGenesis has raised $458.0M across 4 funding rounds.
EGenesis has raised $458.0M in total across 4 funding rounds.
EGenesis has raised $458.0M across 4 funding rounds. Most recently, it raised $190.0M Series D in September 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 1, 2024 | $190M Series D | LUX Capital | ARCH Venture Partners, Biomatics Capital Partners, Khosla Ventures, Leaps BY Bayer, Menlo Ventures, Isaac Ciechanover | Announced |
| Mar 1, 2021 | $130M Series C | — | ARCH Venture Partners, Biomatics Capital Partners, Leaps BY Bayer, LUX Capital, Menlo Ventures, Isaac Ciechanover | Announced |
| Nov 1, 2019 | $100M Series B | AL Wiegman | ARCH Venture Partners, Biomatics Capital Partners, Leaps BY Bayer, LUX Capital, Menlo Ventures, Isaac Ciechanover | Announced |
| Mar 1, 2017 | $38M Series A | ARCH Venture Partners, Biomatics Capital Partners | Leaps BY Bayer, LUX Capital, Menlo Ventures, Isaac Ciechanover | Announced |
EGenesis has raised $458.0M in total across 4 funding rounds.
EGenesis's investors include Lux Capital, ARCH Venture Partners, Biomatics Capital Partners, Khosla Ventures, Leaps by Bayer, Menlo Ventures, Isaac Ciechanover, Al Wiegman.
eGenesis is a biotechnology company developing xenotransplantation solutions using CRISPR-based gene editing to create safe, human-compatible pig organs and cells, targeting the global transplant shortage for kidney failure, islet cell needs, and beyond. Founded in 2015 and headquartered in Cambridge, Massachusetts, it leverages its proprietary EGEN™ platform to produce HuCo™ (human-compatible) organs by inactivating porcine endogenous retroviruses, eliminating pathogen risks, and editing genes to prevent immune rejection.[1][2][3][4] The company serves patients awaiting transplants—hundreds of thousands worldwide facing organ failure—solving the acute shortage where demand far outstrips human donor supply, with lead programs advancing kidney and islet cell transplantation toward clinical reality.[1][2][6]
eGenesis was founded in 2015 in Cambridge, US, emerging from breakthroughs in gene editing and xenotransplantation research to tackle the organ shortage crisis.[4] While specific founders are not detailed in available sources, the company quickly built a leadership team including a President & CEO, Chief Business Officer, Chief Medical Officer, and SVP of Innovation, driving its focus on multiplex genome engineering.[2] Early traction stemmed from advances in CRISPR technology, enabling the inactivation of all endogenous retroviruses in porcine genomes and comprehensive immune rejection mitigation—pivotal steps that addressed historical xenotransplant barriers like cross-species infection and graft failure.[3] This positioned eGenesis at the forefront, partnering with leading medical institutions to translate lab innovations into viable therapies.[3]
eGenesis rides the convergence of CRISPR gene editing, xenotransplantation, and regenerative medicine, addressing a transplant crisis where statistics like millions on waitlists underscore unmet need—e.g., kidney failure patients facing dialysis limitations and type 1 diabetes families seeking islet solutions.[2][5][6] Timing is ideal amid rapid CRISPR advancements and regulatory progress (e.g., FDA nods for similar therapies), amplified by post-pandemic organ demand surges and aging populations straining donor systems.[1][3] Market forces favor it through biotech investment in "platform" technologies like EGEN™, enabling scalable organ production versus one-off human donors, while influencing the ecosystem by pioneering human trials that could normalize xenotransplants, spurring competitors and infrastructure for gene-edited therapies.[3][4]
eGenesis stands poised for clinical milestones, with kidney and islet programs likely advancing to human trials soon, potentially yielding first xenotransplant approvals in the late 2020s amid accelerating regulatory support. Trends like AI-optimized gene editing, expanded pig genome maps, and global organ demand will propel growth, though challenges in scaling production and long-term safety data remain. Its influence could redefine transplantation as an engineered supply chain, transforming patient outcomes and inspiring a new era of biotech scalability—ultimately engineering hope from the global shortage crisis.[2][3][6]
